The science behind aging and how to slow it has never been more compelling, and OneSkin is at the forefront of this rapidly emerging field. The pioneering skin longevity brand, known for leveraging biotech to target the underlying mechanisms of skin aging, has announced a $20 million Series. An investment from growth equity firm Prelude Growth Partners.
The funding round, completed last month, isn’t just about expanding resources; it’s about strategic alignment. In a move that defied industry norms, OneSkin wasn’t actively seeking capital. Instead, Prelude Growth Partners approached the brand directly, driven by their conviction in OneSkin’s mission and market potential. The investment also allowed OneSkin to replace an early seed investor with a partner they believe is better aligned to support their next stage of growth.
“This strategic investment underscores Prelude Growth’s belief in the long-term potential of skin longevity as a category and in OneSkin’s leadership at the forefront of this movement,” the company shared in its announcement.
The Science of Extending “Skinspan”
Founded by a team of female PhD scientists, OneSkin brings a breakthrough philosophy to beauty and skincare: focusing on “skinspan,” the period during which skin remains healthy and functional. Instead of targeting only the surface signs of aging, OneSkin’s research zeroes in on aging at the cellular level, particularly senescent cells.
These senescent cells are aging or dysfunctional cells that build up over time, contributing to inflammation, collagen degradation, and other biological factors connected to wrinkles, sagging, and dullness. OneSkin’s proprietary peptide, OS-01, was developed to reduce the burden of these cells, ultimately aiming to make skin look and behave like younger skin.
This science-based approach has positioned OneSkin as a leader in what experts predict will be one of the fastest-growing sectors within personal care: longevity-focused skincare.
Forming a Dream Team for Growth
For CEO and co-founder Carolina Reis Oliveira, PhD, the Series A investment is about more than money; it’s about partnership:
“We’re incredibly proud to welcome Prelude Growth Partners to the OneSkin family,” said Carolina Reis Oliveira, PhD, Co-Founder and CEO of OneSkin. “Their team’s expertise in building modern consumer brands and their enthusiasm for our science-driven approach made this a natural fit. We weren’t looking for new capital — but their passion and belief in our vision made this an opportunity to expand our resources and work alongside people we deeply admire. We got ourselves a dream team!”
Prelude Growth Partners, based in New York, is well known for backing founder-led consumer brands that eventually become market leaders in sectors like health & wellness, beauty & personal care, food & beverage, and consumer services. The firm’s portfolio notably includes several female-founded companies that have successfully scaled to national or global recognition.
Alicia Sontag, Co-Founder and Managing Partner at Prelude Growth, expressed strong confidence in OneSkin’s category-defining potential. “OneSkin’s cutting edge science, novel proprietary technology, leadership in skin longevity, and compelling brand are truly unique in the category,” said Alicia Sontag. “We are extremely proud to have the opportunity to partner with Carolina, Alessandra and the team at OneSkin to support them in creating an iconic, powerhouse brand of the future.”
Celebrity-Backed and Consumer-Loved
OneSkin is quickly becoming a household name not just in science and investor circles, but among beauty consumers and celebrities alike. The brand’s topical and supplement range, including OS-01 FACE, BODY, and EYE, and newer launches OS-01 LIP and OS-01 HAIR, has cultivated a loyal following. Notably, high-profile fans include Jennifer Aniston, Camila Alves McConaughey, and Katy Perry.
With support from previous investors such as Selva Ventures, Unilever Ventures, Plus Capital, 2Future, SOSV, and Meta Planet, OneSkin’s growth trajectory has already been impressive. The new $20 million Series A sets the stage for accelerated expansion, product innovation, and deeper consumer reach.
Shaping the Next Frontier in Beauty
The skincare category is notoriously crowded, but OneSkin is differentiating itself by focusing on validated biotech research rather than beauty fads. Its OS-01 peptide technology, combined with an unrelenting emphasis on healthy skin longevity, stands out in a market where claims often lack scientific rigor.
By replacing an early-stage investor with a growth partner like Prelude, OneSkin positions itself for smart, strategic scaling, likely including expanded product lines, entry into new retail markets, and broader global distribution.
For consumers, the message is clear: investing in skin health isn’t just about appearance, it’s about preserving the skin’s biological function for as long as possible. That shift in narrative may prove to be the defining factor in OneSkin’s long-term industry leadership.
Looking Ahead
As longevity science gains momentum in both medical and consumer markets, OneSkin’s alignment with a growth equity partner experienced in scaling purpose-driven brands could make it a force to be reckoned with in beauty’s next era.
Their mission to make skin behave as though it’s biologically younger resonates far beyond vanity. It connects to the broader wellness conversation about extending healthspan, not just lifespan. With fresh capital, a new strategic partner, and a growing fan base that bridges the worlds of science, celebrity, and everyday consumers, OneSkin seems poised for a transformative next chapter.
